Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

May 2012 - FRMC

05/24/2012

Mary Mihalovic

Mary Mihalovic
San Francisco—The use of the protease inhibitors boceprevir or telaprevir in conjunction with peginterferon and ribavirin (known as triple therapy) for the treatment of type 1 hepatitis C did not result in increased drug utilization compared...
San Francisco—The use of the protease inhibitors boceprevir or telaprevir in conjunction with peginterferon and ribavirin (known as triple therapy) for the treatment of type 1 hepatitis C did not result in increased drug utilization compared...
San Francisco—The use of the...
05/24/2012
First Report Managed Care
05/24/2012

Tim Casey

Tim Casey
San Francisco—As rare diseases, multiple myeloma and myelofibrosis, are difficult to manage and associated with high costs. Due to new therapies and evolving strategies that are effective but complex, the challenges are increasing. At the...
San Francisco—As rare diseases, multiple myeloma and myelofibrosis, are difficult to manage and associated with high costs. Due to new therapies and evolving strategies that are effective but complex, the challenges are increasing. At the...
San Francisco—As rare diseases,...
05/24/2012
First Report Managed Care
05/24/2012

Tori Socha

Tori Socha
San Francisco—Provisions in the Patient Protection and Affordable Care Act (ACA) call for the establishment of insurance exchanges. These exchanges are intended to provide a competitive marketplace for individuals and employees of small...
San Francisco—Provisions in the Patient Protection and Affordable Care Act (ACA) call for the establishment of insurance exchanges. These exchanges are intended to provide a competitive marketplace for individuals and employees of small...
San Francisco—Provisions in the...
05/24/2012
First Report Managed Care
05/24/2012

Tim Casey

Tim Casey
San Francisco—By 2020, healthcare expenditures in the United States are expected to reach nearly $5 trillion and account for 20% of the country’s gross domestic product (GDP), which is twice as much as in most developed countries. With an...
San Francisco—By 2020, healthcare expenditures in the United States are expected to reach nearly $5 trillion and account for 20% of the country’s gross domestic product (GDP), which is twice as much as in most developed countries. With an...
San Francisco—By 2020,...
05/24/2012
First Report Managed Care
05/24/2012

Eileen Koutnik-Fotopoulos

Eileen Koutnik-Fotopoulos
San Francisco—A step therapy program found that patients with epilepsy who switched to generic formulations had a numerically and statistically significant reduction in costs compared with patients who stayed on brand formulations, based on...
San Francisco—A step therapy program found that patients with epilepsy who switched to generic formulations had a numerically and statistically significant reduction in costs compared with patients who stayed on brand formulations, based on...
San Francisco—A step therapy...
05/24/2012
First Report Managed Care
05/24/2012

Ken Palmer

Ken Palmer
San Francisco—Metastatic melanoma is a rare but rapidly progressing form of cancer that develops in the melanocytes of the skin. The BRAF protein kinase plays an important role in the progression of the disease. Vemurafenib is a BRAF...
San Francisco—Metastatic melanoma is a rare but rapidly progressing form of cancer that develops in the melanocytes of the skin. The BRAF protein kinase plays an important role in the progression of the disease. Vemurafenib is a BRAF...
San Francisco—Metastatic...
05/24/2012
First Report Managed Care
05/24/2012

Tim Casey

Tim Casey
San Francisco—Managed care professionals are increasingly utilizing comparative effectiveness research (CER) to determine the effectiveness, safety, and value of drugs. This detailed approach is particularly useful for patients with high...
San Francisco—Managed care professionals are increasingly utilizing comparative effectiveness research (CER) to determine the effectiveness, safety, and value of drugs. This detailed approach is particularly useful for patients with high...
San Francisco—Managed care...
05/24/2012
First Report Managed Care

Department

Conference Insider
05/24/2012

Kristina Woodworth

Kristina Woodworth
San Francisco—During a Contemporary Issues session at the AMCP meeting, representatives from the FDA Office of Prescription Drug Promotion (OPDP) and the industry reviewed the FDA’s official Guidance for Industry on responding to unsolicited...
San Francisco—During a Contemporary Issues session at the AMCP meeting, representatives from the FDA Office of Prescription Drug Promotion (OPDP) and the industry reviewed the FDA’s official Guidance for Industry on responding to unsolicited...
San Francisco—During a...
05/24/2012
First Report Managed Care
Conference Insider
05/24/2012

Tori Socha

Tori Socha
An advisory work group met to develop a Roadmap for pharmacists to follow to integrate health information technology (HIT) into their practice.
An advisory work group met to develop a Roadmap for pharmacists to follow to integrate health information technology (HIT) into their practice.
An advisory work group met to...
05/24/2012
First Report Managed Care
Conference Insider
05/24/2012

Kevin L. Carter

Kevin L. Carter
San Francisco—Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNFα), is used to treat autoimmune conditions such as psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and...
San Francisco—Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNFα), is used to treat autoimmune conditions such as psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and...
San Francisco—Infliximab, a...
05/24/2012
First Report Managed Care

Advertisement

Advertisement

Advertisement